1. Active extracts of wild fruiting bodies of Antrodia camphorata (EEAC) induce leukemia HL 60 cells apoptosis partially through histone hypoacetylation and synergistically promote anticancer effect of trichostatin A.
- Author
-
Lu MC, Du YC, Chuu JJ, Hwang SL, Hsieh PC, Hung CS, Chang FR, and Wu YC
- Subjects
- Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Dose-Response Relationship, Drug, Drug Synergism, Drug Therapy, Combination, Enzyme Activation drug effects, Gene Expression Regulation, Neoplastic drug effects, HL-60 Cells, Histone Deacetylase Inhibitors, Humans, Hydroxamic Acids toxicity, NF-kappa B metabolism, Receptors, Death Domain drug effects, Receptors, Death Domain metabolism, Antrodia chemistry, Apoptosis drug effects, Enzyme Inhibitors pharmacology, Histones metabolism, Hydroxamic Acids pharmacology, Leukemia drug therapy, Plant Extracts pharmacology
- Abstract
The endemic species of Antrodia camphorate (AC) is a promising chemotherapeutic drug for cancer. We found that the ethanol extract from wild fruiting bodies of Antrodia camphorata (EEAC) could induce HL 60 cells apoptosis via histone hypoacetylation, up-regulation of histone deacetyltransferase 1 (HDAC 1), and down-regulation of histone acetyltransferase activities including GCN 5, CBP and PCAF in dose-dependent manner. In combination with histone deacetylase inhibitor, trichostatin A (TSA), did not block EEAC-induced apoptosis. Interestingly, combined treatment (100 nM of TSA and 100 microg/ml EEAC) caused synergistic inhibition of cell growth and increase of apoptotic induction. EEAC could effectively increase the cytotoxic sensitivity of TSA through the up-regulation of DR5 and NFkappaB activation. In this present study, bioassay-guided fractionation of EEAC led to a major active compound, zhankuic acid A, as the bioactive marker. Moreover, our findings may represent an experimental basis for developing EEAC as a potential chemotherapeutic adjuvant.
- Published
- 2009
- Full Text
- View/download PDF